Sign in
BCAX Stock Price, Chart, Stats & News
Bicara Therapeutics Inc. Common Stock
Save
1.45B
Market cap
–
Current P/E
–
Forward P/E
BCAX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.29% |
ROA | -28.61% |
ROE | -27.17% |
D/E | 0.00x |
Interest coverage ratio | – |
BCAX valuation
P/E | – |
P/S | – |
P/B | 2.49x |
P/CF | -8.87x |
P/FCF | -8.90x |
P/OCF | -8.87x |
PEG | 0.44x |
EV multiple | -8.61x |
About
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers.
Similar securities
Based on sector and market capitalization
Report issue